SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
91,600
+1,300 (1.44%)
Last updated: May 29, 2025
9.05%
Market Cap 7.17T
Revenue (ttm) 578.00B
Net Income (ttm) 251.21B
Shares Out 78.31M
EPS (ttm) 3,207.77
PE Ratio 28.56
Forward PE 42.17
Dividend n/a
Ex-Dividend Date n/a
Volume 114,073
Average Volume 213,900
Open 90,700
Previous Close 90,300
Day's Range 90,700 - 92,200
52-Week Range 72,600 - 130,000
Beta 0.94
RSI 41.82
Earnings Date May 9, 2025

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 241
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.